The increase in price target by HC Wainwright & Co. reflects a positive outlook on Y-mAbs Therapeutics, likely due to the company's strong fundamentals or potential growth opportunities. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term uptick in the stock price.